The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Recent updates on drug resistance in Mycobacterium tuberculosis
Abstract
Tuberculosis (TB) along with acquired immune deficiency syndrome and malaria rank among the top three fatal infectious diseases which pose threat to global public health, especially in middle and low income countries. TB caused by Mycobacterium tuberculosis (Mtb) is an airborne infectious disease and one-third of the world's population gets infected with TB leading to nearly 1·6 million deaths annually. TB drugs are administered in different combinations of four first-line drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) lower availability of less toxic, inexpensive and effective drugs, (iv) long treatment duration, (v) nonadherence to drug regimen and (vi) evolution of drug-resistant TB strains. Drug-resistant TB poses a significant challenge to TB therapy and control programs. In the background of worldwide emergence of 558 000 new TB cases with resistance to rifampicin in the year 2017 and of them, 82% becoming multidrug-resistant TB (MDR-TB), it is essential to continuously update the knowledge on the mechanisms and molecular basis for evolution of Mtb drug resistance. This narrative and traditional review summarizes the progress on the anti-tubercular agents, their mode of action and drug resistance mechanisms in Mtb. The aim of this review is to provide recent updates on drug resistance mechanisms, newly developed/repurposed anti-TB agents in pipeline and international recommendations to manage MDR-TB. It is based on recent literature and WHO guidelines and aims to facilitate better understanding of drug resistance for effective TB therapy and clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer
von Wintersdorff, C. J. H., Penders, J., van Niekerk, J. M., Mills, N. D., Majumder, S., van Alphen, L. B., Savelkoul, P. H. M., & Wolffs, P. F. G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00173 · Cited by 1,707
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Aminoglycoside modifying enzymes
Ramirez, M. S., & Tolmasky, M. E. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.08.003 · Cited by 1,464
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231 · cited 1×
“2) (Piddock 2006; Blair et al. 2015; Nguyen 2016; Nasiruddin et al. 2017).”
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017863 · Cited by 805
Multidrug Tolerance of Biofilms and Persister Cells
Lewis, K. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75418-3_6 · Cited by 804
Cited by
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
Metadata
- Authors
- Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T.
- Venue
- Journal of Applied Microbiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-29
- Volume
- 128
- Issue
- 6
- Pages
- 1547-1567
- ISSN
- 1364-5072 (ISSN-L)
- 1365-2672
- OpenAlex
- W2979328457
- Cited by
- 337
- References
- 81
- FWCI
- 18.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.